Compare UK prices. 40+ products · 22 retailers scored
PeptideClear UK
Bpc 1570:48 Watch on YouTube Read transcript

Bpc 157

Watch above, or read the full transcript below.

Transcript

[0:00] What is BPC-157?

[0:08] BPC-157 is a synthetic peptide. It is a chain of fifteen amino acids derived from a fragment of a protein found in human gastric juice. It was first characterised in the 1990s by the Sikiric research group at the University of Zagreb.

[0:16] Almost everything published on BPC-157 is preclinical. The evidence base is rodent studies, mostly from one research group. Independent replication is limited. There are no published human randomised controlled trials.

[0:24] In the UK, BPC-157 is not a controlled drug. It is not scheduled under the Psychoactive Substances Act. It holds no UK marketing authorisation as a medicine. It is sold legally as a research chemical, for research use only.

[0:32] Full evidence breakdown on peptideclear.co.uk.

[0:40] Full evidence breakdown on peptideclear.co.uk

Not medical advice. PeptideClear is editorial commentary only. Always consult a UK-registered healthcare professional.

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-26T12:00:00.000Z
Trust, Legal and Governance

PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.

Legal and Registration

Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.

Standards and Governance

Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.

Domain Continuity

Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.